🧬 New TALAPRO-3 ctDNA data in HRR-mutated mCSPC at #ESMO26:

• Baseline ctDNA positivity → poorer rPFS in both arms
• ctDNA clearance rates→ higher with TALA+ENZA vs PBO+ENZA
• ctDNA clearance by week 5 → better rPFS in both arms
• Persistently undetectable ctDNA → most favourable outcomes

💡 Take-home: Early ctDNA dynamics show promise for refining prognosis, but are not yet ready to guide routine treatment decisions.

#ProstateCancer #ctDNA